Editas Medicine and BlueRock Therapeutics Enter Strategic Research Collaboration and Cross-Licensing Agreement to Combine Genome Editing and Cell Therapy Platforms
03. April 2019 07:00 ET
|
Editas Medicine, Inc.
– Collaboration enables BlueRock to discover and develop engineered cell medicines broadly across neurology, cardiology and immunology – – Collaboration enables Editas Medicine to discover and...